Search
DP-b99
go.drugbank.com/drugs/DB05820InvestigationalDP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment
Carbon black
go.drugbank.com/drugs/DB11980InvestigationalProduced by the incomplete combustion of hydrocarbons, carbon black is an insoluble pigment [A263396] with demonstrated adverse effects on pulmonary function. … [A263401] Upon inhalation, carbon black has been reported to trigger an inflammatory response in the lung tissue [A263401] and has been linked to carcinogenicity.[A263406, A263411, A263416]
Synonyms: VEGETABLE CARBON (E 153)Telavancin
go.drugbank.com/drugs/DB06402ApprovedInvestigationalMRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others. … Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.
Bradanicline
go.drugbank.com/drugs/DB06090InvestigationalBradanicline belongs to a new class of drugs for the treatment of central nervous system diseases and disorders. … Bradanicline, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7(α7).
Goflikicept
go.drugbank.com/drugs/DB16396InvestigationalGoflikicept is under investigation in clinical trial NCT04380519 (Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe
Synonyms: Heterodimeric fusion protein that binds to IL-1 beta consisting of human extracellular domain of IL1 receptor and a mutant Fc fragment of human IGg1 and part of human IL1 receptor accessory proteinXL765
go.drugbank.com/drugs/DB05241InvestigationalXL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).
LX6171
go.drugbank.com/drugs/DB05180InvestigationalLX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia
Disufenton
go.drugbank.com/drugs/DB17298InvestigationalSynonyms: 4-tert-butyliminomethyl)benzene-,3-disulfonate n-oxide, 4-tert-butyliminomethyl)benzene-,3-disulphonate n-oxideCategories: Compounds used in a research, industrial, or household setting